ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile
Fig 5
ALX148 reduces myeloid-driven immune suppression in tumor.
(A) Schematic of dosing schedule and tissue harvest for immune phenotyping. CT26 colon carcinoma cells were implanted subcutaneously in BALB/c mice and treated on day 10 post-implantation with a single dose of PBS, ALX148, anti-PD-1 or ALX148 + anti-PD-1. 10 days post-treatment, spleen and tumor were harvested for immune phenotyping. (B) Ratio of M1/M2 TAMs in tumor. M1 is defined as CD45+CD11b+CD38+EGR2- and M2 is defined as CD45+CD11b+CD38-EGR2+. Results are representative of two independent experiments of n = 5–7 mice/group. (C) Percent mMDSC in tumor. mMDSC is defined as CD45+CD11b+Ly6ChiMHCII-. Results are representative of two independent experiments of n = 5–6 mice/group. *p<0.05, **p<0.01. Statistics were performed using One-Way ANOVA, Tukey-Kramer.